Invasive Breast Cancer, Breast Cancer Mortality Increased Long Term After DCIS
25 Jan 2024
Clinical Result
THURSDAY, Jan. 25, 2024 -- Women with non-screen-detected ductal carcinoma in situ have an increased risk for invasive breast cancer and breast cancer death, according to a study published online Jan. 24 in The BMJ.
Gurdeep S. Mannu, M.B.B.S., D.Phil., from the University of Oxford in the United Kingdom, and colleagues examined the long-term risks for invasive cancer and death related to breast cancer after non-screen-detected ductal carcinoma in situ among 27,543 women in England who were diagnosed during 1990 to 2018, outside the National Health Service breast screening program.
The researchers found that by Dec. 31, 2018, 3,651 women with non-screen-detected ductal carcinoma in situ had developed invasive breast cancer (ratio of observed to expected rate, 4.21). Throughout follow-up, the ratio of observed to expected rate of developing invasive breast cancer remained elevated among women aged younger than 45 to 70 years. The 25-year cumulative risks for invasive breast cancer were 27.3, 25.2, 21.7, and 20.8 percent for those with a diagnosis of ductal carcinoma in situ at age younger than 45, 45 to 49, 50 to 59, and 60 to 70 years, respectively. Overall, 908 women died of breast cancer (ratio of observed to expected rate, 3.83); the ratio remained elevated throughout follow-up. The 25-year cumulative risks for breast cancer death were 7.6, 5.8, 5.9, and 6.2 percent, respectively, by age at diagnosis.
"These findings should inform considerations regarding the frequency and duration of surveillance following a diagnosis of ductal carcinoma in situ, particularly for women diagnosed at younger ages," the authors write.
Abstract/Full Text
Editorial
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.